Skip to main content

Table 3 Modified Intention to Treat efficacy and effectiveness of studies examining oral PrEP

From: A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?

Characteristics Outcome
Year Study name Population Regimen Drug Efficacy (%, 95 CI)
2010 iPrEx [6] MSM/TGW Daily TDF-FTC 44% (15 to 63)
2012 Partners study [7] Heterosexual HIV-discordant couples Daily TDF-FTC 75% (55 to 87)
TDF 67% (44 to 81)
2012 TDF2 [8] Heterosexual Daily FTC- TDF 62.2% (21.5 to 83.4)
2012 FEM-PrEP [13] Heterosexual Females Daily TDF-FTC 6% (−52 to 41%)
2013 Bangkok tenofovir study [31] PWID Daily TDF 48.9% (9.6 to 72.2)
2014 iPrEx extension [15] MSM/TGW Daily TDF-FTC 36% (−24 to 67)a
2015 VOICE [14] Heterosexual Females Daily TDF-FTC −4% (−49 to 27)
TDF −49% (− 129 to 3)
2015 PROUD [9] MSM Daily TDF-FTC 86% (90% CI 64 to 96)
2015 IPERGAY [10] MSM/TGW Event-driven TDF-FTC 86% (40 to 98)
  1. a Unknown if intention to treat or modified intention to treat. MSM men who have sex with men, TGW transgender women, PWID people who inject drugs, TDF tenofovir, FTC emtricitabine